Skip to main content

Dr. Stein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Stein's full profile

Already have an account?

Education & Training

  • Fitzsimons Army Medical Center
    Fitzsimons Army Medical CenterResidency, Internal Medicine, 1975 - 1977
  • Letterman Army Medical Center
    Letterman Army Medical CenterResidency, Internal Medicine, 1972 - 1975
  • University of Colorado School of Medicine/National Jewish Health (Adult)
    University of Colorado School of Medicine/National Jewish Health (Adult)Residency, Allergy and Immunology, 1968 - 1970
  • Abington Memorial Hospital
    Abington Memorial HospitalInternship, Transitional Year, 1968 - 1969
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1968

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1971 - Present
  • FL State Medical License
    FL State Medical License 1979 - 2025
  • PA State Medical License
    PA State Medical License 1969 - 1992
  • MD State Medical License
    MD State Medical License 1977 - 1983
  • CO State Medical License
    CO State Medical License 1975 - 1979
  • American Board of Allergy and Immunology Allergy & Immunology
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Whos Who in Medicine and Healthcare Marquis Whos Who
  • Top MD Consumers Checkbook
  • Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin Therapy
    CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin TherapyMarch 6th, 2017
  • Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America
    Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North AmericaMarch 7th, 2016

Professional Memberships

Hospital Affiliations